Andrea Pirzkall

Andrea Pirzkall, MD, is the Chief Medical Officer of Asher Bio and is responsible for building and overseeing the clinical development organization. She has over 15 years of clinical development experience in large and smaller biotechnology/pharmaceutical companies, spanning global roles and accountabilities in the US, EU and Asia-Pacific regions, and a track record of success in evaluating and advancing cancer therapeutics through all stages of development, with a focus on first-in-human to proof of concept and pivotal studies.

Most recently, Andrea served as Chief Medical Officer at Replimune, where she was responsible for building the clinical development organization and leading the clinical development of its pipeline of oncolytic immuno-gene therapies. Prior to this, she served as Executive Director, Clinical Development at BeiGene, Ltd. where she was primarily responsible for the development of its anti-PD-1 inhibitor tislelizumab and served as the clinical development lead during the partnership with Celgene Corporation. Previously, Dr. Pirzkall had a 10-year tenure at Genentech, Inc., where she led the development of several novel biologic agents (signaling pathway inhibitors, anti-angiogenesis, and immunotherapy agents) in early to late-stage development in solid tumor oncology.

Prior to her move to industry, Dr. Pirzkall was an Associate Adjunct Professor of Radiation Oncology, Radiology, and Neurosurgery at the University of California, San Francisco, where she also completed a fellowship in Radiation Oncology and Medical Physics. Dr. Pirzkall obtained her MD from Friedrich-Schiller University, Jena, and completed her residency and dissertation in Radiation Oncology at Ruprecht-Karls University & German Cancer Research Center, Heidelberg, Germany.